REBOHIL (BGM-1, BGM-2, BGM-3, BGM-4, BGM-5)
Hyundai Bioland Co., Ltd. · Decision date Sep 25, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 09/25/2026 for REBOHIL (BGM-1, BGM-2, BGM-3, BGM-4, BGM-5), submitted by Hyundai Bioland Co., Ltd. of Cheongju-Si, Republic of Korea, under 510(k) number K254210. The application was received 12/29/2025 and reviewed as a traditional 510(k) by the Dental panel; it was not reviewed by a third party, not a combination product, and no predetermined change control plan was authorized. SESE means the device was cleared for marketing, not approved under a PMA.
The listed classification is Bone Grafting Material, Animal Source, regulation 872.3930, product code NPM, in the Dental medical specialty. The record identifies five model designations (BGM-1 through BGM-5) but does not state what distinguishes them, what the device is composed of, or which predicate device the equivalence finding rests on. The public summary field is empty, so the indications for use, materials, and any supporting performance data remain unknown from this source.
Readers should treat the clearance as a regulatory status record only. No clinical, safety, or comparative effectiveness conclusion follows from the decision, and the absence of a summary in the retrieved page limits any assessment of the basis for the equivalence determination.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Dental
- Decision date
- Sep 25, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K254210
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Hyundai Bioland Co., Ltd.
- Product code
- NPM
- Decision code
- SESE
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Bone Grafting Material, Animal Source.
- Applicant
- Hyundai Bioland Co., Ltd.
- Product code
- NPM
- FDA device class
- 2
FDA decision timeline
K254210 received
Application receipt date recorded by FDA.
K254210 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code NPM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Wishbone HAEK260096 | Wishbone SA | 510(k) clearance | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Hyundai Bioland Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Cheongju-Si
Sources and methodology
- Original FDA record: K254210
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records